Answers are grounded in this paper and cite their sources.
This article refers to ‘Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension’ by M. D'Alto et al., published in this issue on pages 817–824. Pulmonary congestion (or oedema) is a key feature of the heart failure (HF) syndrome and associated with dyspnoea, a decrease in exercise tolerance, and morbidity. Over the past two decades, lung ultrasound (LUS) has gained increasing popularity as a non-invasive and sensitive tool for the detection of pulmonary congestion in patients with or at risk for HF in a variety of research and clinical settings. So-called ‘B-lines’ on LUS are reverberation artefacts that appear as vertical lines and extend from the pleural line towards the far-field of the ultrasound screen. B-lines are markers of increased lung density and can be quantified in one intercostal space across several areas of the chest (also called ‘zones’). In patients presenting with undifferentiated dyspnoea to the emergency department, the detection of ≥3 B-lines in at least 2 zones on each hemithorax (i.e. at least 12 B-lines in total across 8 zones) identifies patients with acute HF with higher accuracy than the combination of natriuretic peptides and chest x-ray.1 As a result, LUS has been incorporated in the diagnostic strategy for patients with suspected acute HF in the 2021 European Society of Cardiology HF guidelines.2 B-lines change with the degree of pulmonary congestion: they decrease with diuresis and increase with infusion of intravenous fluids in patients with HF.3, 4 The presence of multiple B-lines is also associated with an increased risk of subsequent HF hospitalizations or death both in hospitalized patients with acute HF and in ambulatory HF cohorts.5 Despite this significant body of literature on the utility of LUS in patients with HF, it has been unclear whether pulmonary congestion on LUS could also be detected in patients with pulmonary arterial hypertension (PAH) who have a normal pulmonary capillary wedge pressure and develop HF as a result of right ventricular dysfunction and not left heart disease (isolated post-capillary pulmonary hypertension). In this issue of the Journal, the study by D'Alto and colleagues sought to address this question by assessing the presence of sonographic B-lines in 102 adults with suspected idiopathic PAH undergoing echocardiography, 8-zone LUS, and invasive haemodynamic assessment at rest.6 All three examinations were performed within 1 h of each other in this single-centre study. In addition, patients underwent pulmonary function testing and chest computed tomography (CT) to exclude pulmonary conditions as the aetiology of PAH, as well as N-terminal pro-brain natriuretic peptide (NT-proBNP) testing. The authors found that 75% of patients had any B-lines with a median of 3 B-lines across 8 zones and a median NT-proBNP level of 377 pg/ml. In multivariable analyses, invasively measured higher right atrial pressure, lower echocardiographic tricuspid annular plane systolic excursion/pulmonary artery systolic pressure ratio and higher NT-proBNP levels were independent predictors of B-lines. The authors concluded that B-lines are a common finding in patients with idiopathic PAH, and that this finding is related to right ventricular–pulmonary artery uncoupling. They hypothesize that this may be due to increased central venous pressure impeding lymphatic outflow as opposed to increased pulmonary vascular hydrostatic pressures. To our knowledge, this is one of the first publications to explore the relationship between B-lines on LUS and invasive haemodynamics in patients with idiopathic PAH. The authors previously compared LUS findings in a smaller cohort of patients with PAH to a group with HF with preserved ejection fraction (HFpEF) and found that those with HFpEF had a significantly higher B-line count across 8 zones both before and after infusion of intravenous fluids (7 ml/kg of saline), although a subset of patients in the PAH group did have detectable B-lines at baseline, as well.4 The current work expands on these earlier findings by providing insights into the predictors of sonographic B-lines in a larger cohort of patients with idiopathic PAH. The current findings suggest that in addition to elevated pulmonary venous pressures, elevated pulmonary artery pressures even in the absence of elevated pulmonary venous pressures can lead to pulmonary congestion that can be detected by LUS at rest (Figure 1 and Table 1).4, 6-12 Although there was no direct comparison group in the present study, earlier work (Table 1) would suggest that the degree of pulmonary congestion may be higher (as evidenced by a higher number of B-lines) in patients with left-sided heart disease – both at rest and with exercise. It should be noted that both heterogeneity of some of these earlier patient cohorts and variability in LUS imaging protocols and B-line quantification make direct comparisons of these studies difficult (Table 1). Publication checklists for LUS-related manuscripts have been published and their use would facilitate transparent and standardized reporting, complementing more general reporting guidelines, such as those provided by the Equator network (www.equator-network.org).13 Interestingly, both elevated natriuretic peptide levels and the degree of right ventricular systolic dysfunction in relation to pulmonary artery pressures were predictors of pulmonary congestion on LUS. This lends further support to the hypothesis that right ventricular–pulmonary artery uncoupling and resulting elevation of central venous pressure may impede lymphatic flow and lead to pulmonary oedema and increased B-lines. This is very similar to the pathophysiology hypothesized in the development of pleural and pericardial effusions in isolated PAH.14 Strengths of the current manuscript include the use of chest CT to rule out primary pulmonary pathologies, such as interstitial lung disease or pulmonary fibrosis as the aetiology of B-lines, since B-lines are not specific for extravascular lung water and represent increased tissue density, which is attributed to lung water in patients with left heart disease. It should be noted that among some patients with PAH, there is phenotypic drift of their pulmonary capillary wedge pressure over time, and it increases to resemble that of patients with left heart disease-related pulmonary hypertension and lung congestion.15 The availability of chest CT findings in this study also allowed the authors to report on the prevalence of ground glass opacities on CT in relation to B-lines. This is important as ground glass opacities have recently been reported in a large proportion of patients with PAH in the absence of an increase in pulmonary capillary wedge pressure.16 However, as the timing of CT in relation to LUS was not reported, pulmonary congestion may have changed in the meantime, as the degree of congestion is dynamic and can change within minutes to hours.3 It is also plausible that the correlation between B-lines and ground glass opacities would be different if the studies were performed contemporaneously. The authors also reported broadly on the presence of cardiovascular comorbidities without providing further details to understand if these were comorbidities associated with increased left heart filling pressures and lung congestion. The authors should be congratulated on their important work which expands our current understanding of the relationship between invasive haemodynamic measures and B-lines on LUS in patients with PAH. The present findings suggest that isolated PAH in the absence of left-sided heart disease may cause pulmonary congestion, even at rest. However, this presumes that B-lines (and potentially ground glass opacities) represent water and not some other pathology associated with PAH, such as perivascular fibrosis or inflammation. The authors also suggest that lymphatic obstruction is the mechanism to explain lung congestion among patients with PAH but did not evaluate this directly. Taken together, this study suggests that all these factors should be considered in the evaluation of patients who present with undifferentiated dyspnoea in the absence of left-sided heart disease. What remains unclear is whether B-lines on LUS in patients with idiopathic PAH are associated with worse morbidity and mortality, and whether they are modifiable with therapy in this population. Therefore, additional research will be necessary to understand how LUS can be used as a tool in the assessment and management of patients with PAH. Conflict of interest: E.P.'s employer has received support from Novartis for consulting work, and she has consulted for scPharmaceuticals outside of the submitted work. She has received research support from the NIH (R01HL148439), the American Heart Association and AstraZeneca, and she serves on a clinical trial steering committee for Boehringer Ingelheim. J.A.L. has received research support from the NIH (U01125215) and the American Heart Association and salary support from the Massachusetts Medical Society.
No takes yet. Share an insight, caveat, or question.
Platz et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: